Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7891)	11/30/1998 5:36:00 PM
From: aknahow	Respond to of 17367

"You don't put 90 day follow up before possible trial design change, do you?" I am not sure what you mean by the above. I see any change in the lookback period as a change in trial design. I am not adverse to such changes. In the past it was made clear that they are not talking about changing the dosing, or the Glasgow scale entrance point or etc. Suppose that by adding 50 more patients the statistical confidence level could be significantly increased. The first quarter of the year is the season of major incidence in the U.K. Lab confirmed cases should hit about 90 per week. This would mean that accruals could be increased significantly in a short period of time. Suppose you add one month of accruals but reduce or eliminate the lookback. Have no idea what will be done, just not convinced that any and all changes are automatically bad.